quiverquant.comOct 13$JNJ

JOHNSON & JOHNSON ($JNJ) Releases Q3 2026 Earnings

Johnson & Johnson ($JNJ) reported Q3 2026 earnings of $2.59 per share, meeting estimates, with revenue of $25.4B, missing estimates by $179M. Insiders sold shares, while hedge funds increased positions. Analysts' price targets range from $265 to $298.

Original reporting

quiverquant.com

Published Oct 13, 2026, 11:00 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 13, 2026, 11:43 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

JOHNSON & JOHNSON ($JNJ) Releases Q3 2026 Earnings — source image — Source · quiverquant.com

Decision brief

The 30-second read

$JNJNeutralMed

Why it matters

The earnings miss may trigger short‑term selling pressure, but the stable EPS and dividend yield could provide support for long‑term holders.

Market read

First‑report earnings for a large‑cap health care stock; relevant for traders monitoring earnings-driven moves.

What to watch

Insider sales and hedge fund outflows may signal deeper concerns beyond the earnings numbers.

Relevance 8/10Novelty 8/10Timing: today

Background

The article is an earnings release summary from Quiver Quantitative, providing raw financial results and ancillary data such as insider trades and institutional holdings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JNJNeutralHigh confidence

Context

Johnson & Johnson reported Q3 2026 earnings of $2.59 EPS (meeting estimates) and revenue of $25.4B (missing estimates).

Expected impact

likely modest downside pressure as revenue shortfall outweighs EPS beat

Evidence & confidence

Large‑cap earnings release with revenue below consensus typically drags price, while EPS in line provides limited support.

Market effects

Sector

Healthcare sector may see slight pullback as a major pharma player missed revenue expectations.

Regional

U.S. market may experience modest weakness in defensive stocks.

Global

Limited global impact; JNJ is a multinational but the earnings miss is U.S.-centric.

Counterpoint

What could challenge this read

Despite revenue miss, strong cash flow and dividend yield could attract income investors.

Key entities

company
Johnson & Johnson
U.S. healthcare conglomerate reporting Q3 2026 results.

Read at source ← All news

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.comNov 4

$JNJMedAI 8/10

Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

finance.yahoo.comNov 2

$JNJMed

TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.

imt.ieNov 2

$JNJMed

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

medicaldevice-network.comNov 2

$JNJMedAI 8/10

J&J's Javelin Meets Pivotal Coronary Study Goals; Highlights Impella Survival Data At TCT

Johnson & Johnson (JNJ) reported that its Shockwave Javelin coronary catheter met primary endpoints in the FORWARD CAD study, with 93.6% successful lesion crossing and 93.4% safety. The study involved 158 patients. Separately, J&J shared favorable Impella data from three analyses, showing low mortality rates. JNJ closed at $273.20, down 0.73%.

rttnews.comNov 2

$JNJHigh

PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

endocrinologyadvisor.comNov 2